Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer
Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures An Analysis of the...
Gralla, Richard J.
2008-01-01 00:00:00
ORIGINAL ARTICLE Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer Filippo de Marinis, MD,* Jose Rodrigues Pereira, MD,† Frank Fossella, MD,‡ Michael C. Perry, MD,§ Martin Reck, MD, Marc Salzberg, MD,¶ Jacek Jassem, MD,# Patrick Peterson, PhD,** Astra M. Liepa, PharmD,** Patti Moore, MS,** and Richard J. Gralla, MD†† stable disease (p 0.01), with greater improvement associated with Background: Patients with advanced non-small cell lung cancer response. Median TWS for each LCSS item ranged between 2.3 (NSCLC) require care that emphasizes symptom palliation in addi- months (fatigue) and 7.0 months (cough), with correlation between tion to extending survival. The low response rates and minimal TWS and PFS and OS (all p values 0.017). survival gains observed in second-line studies underscore the need Conclusions: For most NSCLC patients, second-line chemotherapy to assess treatment efficacy with symptomatic end points. provides symptomatic improvement that is linked to standard effi- Methods: To characterize the relationship between patient-reported cacy outcomes. Health-related quality of life data provides comple- health-related quality of life outcomes and efficacy end points mentary efficacy information that can guide routine
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngJournal of Thoracic OncologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/lung-cancer-symptom-scale-outcomes-in-relation-to-standard-efficacy-zHngdM0YwB
Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer
ORIGINAL ARTICLE Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer Filippo de Marinis, MD,* Jose Rodrigues Pereira, MD,† Frank Fossella, MD,‡ Michael C. Perry, MD,§ Martin Reck, MD, Marc Salzberg, MD,¶ Jacek Jassem, MD,# Patrick Peterson, PhD,** Astra M. Liepa, PharmD,** Patti Moore, MS,** and Richard J. Gralla, MD†† stable disease (p 0.01), with greater improvement associated with Background: Patients with advanced non-small cell lung cancer response. Median TWS for each LCSS item ranged between 2.3 (NSCLC) require care that emphasizes symptom palliation in addi- months (fatigue) and 7.0 months (cough), with correlation between tion to extending survival. The low response rates and minimal TWS and PFS and OS (all p values 0.017). survival gains observed in second-line studies underscore the need Conclusions: For most NSCLC patients, second-line chemotherapy to assess treatment efficacy with symptomatic end points. provides symptomatic improvement that is linked to standard effi- Methods: To characterize the relationship between patient-reported cacy outcomes. Health-related quality of life data provides comple- health-related quality of life outcomes and efficacy end points mentary efficacy information that can guide routine
Journal
Journal of Thoracic Oncology
– Wolters Kluwer Health
Published: Jan 1, 2008
Recommended Articles
Loading...
References
Second-line treatment for advanced non-small cell lung cancer: a systematic review
Barlesi
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline
Noble
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
Hanna
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS)
Hollen
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale
Hollen
Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel
de Marinis
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Bezjak
Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy
Peterson
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green
Evaluating clinical versus statistical significance with the LCSS quality of life instrument and the Karnofsky Performance Status (KPS)
Hollen
Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures
Guyatt
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation
Norman
Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer
Hollen
Nonparametric estimation from incomplete observations
Kaplan
A concordance test for independence in the presence of censoring
Oakes
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)
Hollen
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial
Dancey
The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials
Bergman
Interpreting the significance of changes in health-related quality-of-life scores
Osoba
Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer
Bukowski
Share the Full Text of this Article with up to 5 Colleagues for FREE
Sign up for your 14-Day Free Trial Now!
Read and print from thousands of top scholarly journals.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
